Phase III Clinical Trials CROs in South Korea

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

South Korean CRO specializing in clinical trial management and data services for pharmaceutical companies developing products for both Korean and global regulatory submissions.

Clinical development arm of CJ HealthCare, providing Phase I-IV clinical trial management, BA/BE studies, and regulatory support services across South Korea with access to CJ's hospital network.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

Clinical research division of South Korea's Ildong Pharmaceutical group, conducting domestic and international Phase I-IV studies with access to major Korean academic medical centres.

South Korean CRO providing Phase I-IV clinical development, bioanalytical services, and regulatory consulting with particular expertise in simultaneous MFDS-FDA-EMA regulatory submissions.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

Seoul-based niche CRO specializing in dermatology and cosmetic clinical trials, providing IRB-approved study design, site management, and regulatory filing for K-beauty and pharmaceutical skincare products.

Syneos Health's Korean operations providing full-service clinical development support for Korean and global pharmaceutical companies conducting trials in South Korea and APAC markets.